Outcomes with chimeric antigen receptor t-cell therapy in relapsed or refractory acute myeloid leukemia: a systematic review and meta-analysis

Frontiers in Immunology

Immunology

Nausheen Ahmed¹  Joseph P. McGuirk¹  Andrea Nguyen¹  Forat Lutfi¹  Fatima Ali¹  Atif Butt¹  Muhammad Umair Mushtaq¹  Iqra Anwar¹  Ezza Tariq¹  Sibgha Gull Chaudhary¹  Ali Hussain¹  Anurag K. Singh¹  Moazzam Shahzad²  Muhammad Salman Faisal³  Peiman Hematti⁴  Mohammad Ammad-Ud-Din⁵ 

[1] Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States;Division of Hematologic Malignancies & Cellular Therapeutics, University of Kansas Medical Center, Kansas City, KS, United States;Moffitt Cancer Center, University of South Florida, Tampa, FL, United States;Division of Hematology/Oncology, Roswell Park Cancer Institute Buffalo, NY, United States;Division of Hematology/Oncology, University of Wisconsin School of Medicine & Public Health, Madison, WL, United States;Moffitt Cancer Center, University of South Florida, Tampa, FL, United States;

关键词: acute myeloid leukemia;    relapsed or refractory AML;    chimeric antigen receptor T cell therapy;    outcomes;    immunotherapy;   

DOI  :  10.3389/fimmu.2023.1152457

 received in 2023-01-27, accepted in 2023-04-11,  发布年份 2023

来源: Frontiers

【 摘 要 】

BackgroundWe conducted a systematic review and meta-analysis to evaluate outcomes following chimeric antigen receptor T cell (CAR-T) therapy in relapsed/refractory acute myeloid leukemia (RR-AML).MethodsWe performed a literature search on PubMed, Cochrane Library, and Clinicaltrials.gov. After screening 677 manuscripts, 13 studies were included. Data was extracted following PRISMA guidelines. Pooled analysis was done using the meta-package by Schwarzer et al. Proportions with 95% confidence intervals (CI) were computed.ResultsWe analyzed 57 patients from 10 clinical trials and 3 case reports. The pooled complete and overall response rates were 49.5% (95% CI 0.18-0.81, I2 =65%) and 65.2% (95% CI 0.36-0.91, I2 =57%). The pooled incidence of cytokine release syndrome, immune-effector cell associated neurotoxicity syndrome, and graft-versus-host disease was estimated as 54.4% (95% CI 0.17-0.90, I2 =77%), 3.9% (95% CI 0.00-0.19, I2 =22%), and 1.6% (95%CI 0.00-0.21, I2 =33%), respectively.ConclusionCAR-T therapy has demonstrated modest efficacy in RR-AML. Major challenges include heterogeneous disease biology, lack of a unique targetable antigen, and immune exhaustion.

【 授权许可】

Unknown   
Copyright © 2023 Shahzad, Nguyen, Hussain, Ammad-Ud-Din, Faisal, Tariq, Ali, Butt, Anwar, Chaudhary, Lutfi, Ahmed, Singh, Hematti, McGuirk and Mushtaq